Efficacy of vemurafenib in a trametinib-resistant stage IV melanoma patient-letter

Clinical Cancer Research

Volumn 20, Issue 9, 2014, Pages 2498-2499

  Bernhardt, Mathias ^a,b   Orouji, Elias ^a,b   Larribere, Lionel ^a,b   Gebhardt, Christoffer ^a,b   Utikal, Jochen ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; TRAMETINIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE; SULFONAMIDE;

ADULT; CARDIOTOXICITY; CASE REPORT; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; GENE MUTATION; HUMAN; LETTER; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MELANOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TACHYCARDIA; ANTAGONISTS AND INHIBITORS; CANCER STAGING; DRUG RESISTANCE; FATALITY; GENETICS; METABOLISM; PATHOLOGY; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FATAL OUTCOME; HUMANS; INDOLES; MALE; MELANOMA; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDONES; PYRIMIDINONES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84899744464     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2349     Document Type: Letter

References (5)

1. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012;367:107-14.
2. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367:1694-703.
3. Romano E, Pradervand S, Paillusson A, Weber J, Harshman K, Muehlethaler K, et al. Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression. Clin Cancer Res 2013;19:5749-57.
4. Kim KB, Kefford R, Pavlick AC, Infante JR, Ribas A, Sosman JA, et al. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 2013;31:482-9.
5. Goldinger SM, Murer C, Stieger P, Dummer R. Upstream MAPK pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients. Eur J Cancer 2014;50:406-10.